Financial Contrast: ReNeuron Group (OTCMKTS:RNUGF) versus TransCode Therapeutics (NASDAQ:RNAZ)

ReNeuron Group (OTCMKTS:RNUGF) and TransCode Therapeutics (NASDAQ:RNAZ) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Earnings & Valuation

This table compares ReNeuron Group and TransCode Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReNeuron Group	$640,000.00	N/A	-$6.52 million	N/A	N/A
TransCode Therapeutics	N/A	N/A	-$16.75 million	($27.24)	-0.32

ReNeuron Group has higher revenue and earnings than TransCode Therapeutics.

Risk & Volatility

ReNeuron Group has a beta of -0.62, indicating that its stock price is 162% less volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for ReNeuron Group and TransCode Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReNeuron Group	0	0	0	0	0.00
TransCode Therapeutics	1	0	1	0	2.00

TransCode Therapeutics has a consensus target price of $280.00, indicating a potential upside of 3,133.26%. Given TransCode Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe TransCode Therapeutics is more favorable than ReNeuron Group.

Profitability

This table compares ReNeuron Group and TransCode Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReNeuron Group	N/A	N/A	N/A
TransCode Therapeutics	N/A	-440.64%	-205.50%

About ReNeuron Group

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

About TransCode Therapeutics

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.